An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Inclusion Criteria:

• Male and female subjects aged 18-65 years, inclusive
• BMI >18 and <40
• Minimum affected BSA of 10%
• PASI score ≥ 12
• PGA ≥ 3
• Diagnosed with moderate-to-severe plaque psoriasis

Exclusion Criteria:

• Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
• History of an allergic reaction or known and/or significant sensitivity to study drug